新華醫療(600587.SH):公司產品獲得二類、三類醫療器械註冊證
格隆匯 2 月 2日丨新華醫療(600587.SH)公佈,公司於近日收到國家藥品監督管理局和山東省藥品監督管理局頒發的《中華人民共和國醫療器械註冊證》,分別為X射線血液輻照設備,數字化乳腺X射線機。
X射線血液輻照設備的批准上市使我公司成為截至目前國內唯一一家同時擁有γ射線及X射線血液輻照設備產品註冊證的廠家,能夠為客户提供多種選擇,是對公司現有產品的有效補充,進一步豐富了新華醫療放射診療產品線,有利於提升公司的核心競爭力。
數字化乳腺X射線機是新華醫療在診斷X射線設備的技術突破,為未來乳腺X射線系列產品的開發奠定了基礎,有利於豐富公司產品線,有助於提高公司同類產品市場佔有率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.